Lipodystrophy Clinical Trial
Official title:
Open, Non-comparative, Multicentre Clinical Investigation to Evaluate the Performance and Safety of the Medical Device Auralya® (Hyaluronic Acid-dermal Filler) in the Treatment of Facial Dermal Tissue Defects
The Research Question of the present study is the following: in a population of men and women presenting facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects) will cross-linked hyaluronic acid (Auralya®) significantly decrease and / or improve their appearance, results observed after 4, 8 and 12 weeks?
Auralya® action is to increase the volume of dermal-epidermal tissue based on the natural ability of hydrophilic hyaluronic acid molecules to bind to an amount of water many times greater than their weight. This allows to fill the intradermal spaces and integrate the intercellular matrix, conferring turgidity to the tissues. The cross-linking of the hyaluronic acid contained in the product has the effect of more stable and durable filling over time. These characteristics allow Auralya® to be used as a temporary filler for subcutaneous areas to correct small defects in the dermal tissue due to lipodystrophies or the presence of fibrotic tissues as scars, caused by pathologies or trauma. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05419037 -
Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
|
||
| Recruiting |
NCT03059121 -
The Cleveland Cardiometabolic Cohort
|
||
| Completed |
NCT00656175 -
Raltegravir Therapy for Women With HIV and Fat Accumulation
|
Phase 2 | |
| Completed |
NCT00006185 -
Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome
|
Phase 1 | |
| Completed |
NCT00202241 -
The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS
|
N/A | |
| Recruiting |
NCT02262832 -
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
|
Phase 3 | |
| Completed |
NCT01679197 -
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
|
Phase 2 | |
| Completed |
NCT02647853 -
Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers
|
Phase 1 | |
| Active, not recruiting |
NCT00715546 -
Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy
|
Phase 1 | |
| Completed |
NCT00069004 -
A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth
|
N/A | |
| Completed |
NCT00025883 -
Leptin to Treat Lipodystrophy
|
Phase 2 | |
| Completed |
NCT00001142 -
Metabolism and Body Shape of Healthy Children and Children With Chronic Infections
|
N/A | |
| Active, not recruiting |
NCT02262806 -
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
|
Phase 2 | |
| Completed |
NCT02258685 -
Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.
|
||
| Completed |
NCT00192621 -
Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects
|
Phase 4 | |
| Completed |
NCT00006190 -
A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy
|
Phase 4 | |
| Recruiting |
NCT05930106 -
Carotid Doppler Peak Velocity Variation in Liposuction Fluid Management
|
N/A | |
| Completed |
NCT00004329 -
Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy
|
N/A | |
| Recruiting |
NCT04656054 -
Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance
|
||
| Completed |
NCT00082628 -
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
|
Phase 3 |